Table of Contents
Thrombosis
Volume 2013, Article ID 640723, 18 pages
http://dx.doi.org/10.1155/2013/640723
Review Article

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups

1Division of Pharmacology and Clinical Evaluation, Medicines for Human Use, Spanish Agency for Medicines and Medical Devices (AEMPS), c/Campezo 1, Edificio 8, 28022 Madrid, Spain
2Department of Clinical Pharmacology, Hospital Clínico San Carlos, c/Prof. Martín Lagos s/n, 28040 Madrid, Spain
3Department of Pharmacology, Universidad Complutense, Plaza Ramón y Cajal s/n, Ciudad Universitaria, 28040 Madrid, Spain
4Department of Clinical Pharmacology, Hospital Clínic, University of Barcelona, c/Villarroel 170, 08036 Barcelona, Spain

Received 26 June 2013; Accepted 11 September 2013

Academic Editor: Omer Iqbal

Copyright © 2013 Antonio Gómez-Outes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Antonio Gómez-Outes, Ana Isabel Terleira-Fernández, Gonzalo Calvo-Rojas, M. Luisa Suárez-Gea, and Emilio Vargas-Castrillón, “Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups,” Thrombosis, vol. 2013, Article ID 640723, 18 pages, 2013. https://doi.org/10.1155/2013/640723.